Acute decompensated heart failure represents one of the most frequent causes of emergency department visits and unplanned hospital admissions worldwide. Consequently, achieving rapid, safe, and sustained decongestion remains a primary therapeutic objective during acute inpatient admissions. Recent clinical evidence has highlighted the transformative potential of sodium-glucose cotransporter-2 (SGLT2) inhibitors across the spectrum of left ventricular ejection fraction. The latest prespecified analysis of the DAPA ACT HF-TIMI 68 trial provides crucial clinical insights into how in-hospital initiation of dapagliflozin accelerates systemic decongestion and enhances diuretic responsiveness in hospitalized patients.

Rationale for In-Hospital Initiation of Dapagliflozin

Managing acute congestion requires rapid fluid removal without compromising renal function or hemodynamic stability. Traditionally, clinicians relied almost exclusively on intravenous loop diuretics to achieve clinical euvolemia. However, escalating loop diuretic doses frequently triggers neurohormonal activation, worsening renal function, and persistent diuretic resistance. Consequently, contemporary clinical guidelines advocate for early multi-pathway decongestion strategies during the inpatient phase.

The DAPA ACT HF-TIMI 68 study investigated whether starting SGLT2 inhibition during hospitalization optimizes decongestive trajectories. Initiating guideline-directed medical therapy prior to hospital discharge overcomes therapeutic inertia and ensures long-term medication adherence. Furthermore, SGLT2 inhibitors provide modest osmotic diuresis and natriuresis without stimulating the sympathetic nervous system. Therefore, clinicians can achieve effective decongestion while preserving systemic hemodynamics and renal perfusion. This mechanistic advantage makes early therapy initiation an attractive clinical strategy for acute stabilization.

Study Design and Congestion Assessment Methods

The DAPA ACT HF-TIMI 68 trial enrolled 2,401 hospitalized heart failure patients across diverse ejection fraction categories following initial clinical stabilization. Researchers randomized participants to receive either oral dapagliflozin 10 mg once daily or a matching placebo. In this prespecified secondary analysis, investigators rigorously tracked multiple decongestion parameters at 1 week, 1 month, and 2 months post-randomization.

Specifically, the investigators measured serial changes in the modified EVEREST Composite Congestion Score (CCS), which evaluates orthopnea, jugular venous pressure, and peripheral edema. Additionally, they assessed changes in body weight and daily loop diuretic requirements, standardized to intravenous furosemide equivalents. Diuretic efficiency was calculated as net weight loss per unit of loop diuretic administered. At baseline, 12% of patients had no congestion (CCS 0), 63% presented with mild-to-moderate congestion (CCS 1-3), and 24% exhibited severe congestion (CCS 4-9). This diverse distribution mirrored real-world acute heart failure populations.

Early and Sustained Improvements in Decongestion Endpoints

The study results revealed rapid, clinically meaningful benefits across all primary decongestion metrics. By one week, patients receiving dapagliflozin achieved significant reductions in their Composite Congestion Score compared to placebo (least squares mean difference [LSMD]: -0.18; 95% CI: -0.33 to -0.04; P = 0.011). Furthermore, dapagliflozin led to greater early weight loss (LSMD: -0.60 kg; 95% CI: -0.95 to -0.26).

Importantly, these favorable decongestive trajectories persisted throughout the two-month follow-up period. Patients in the dapagliflozin cohort required lower mean daily maintenance doses of loop diuretics compared to the placebo group. Consequently, diuretic efficiency improved substantially at week 1 (LSMD: -0.93 kg per 40 mg furosemide IV equivalent; P = 0.008) and continued to increase progressively over time. This finding demonstrates that dapagliflozin provides both rapid symptom relief and sustained fluid balance regulation without escalating loop diuretic exposure.

Mechanisms Beyond Simple Osmotic Diuresis

The rapid improvements observed at one week reflect the direct tubular effects of SGLT2 inhibition on proximal sodium and glucose reabsorption. By inhibiting SGLT2, dapagliflozin promotes glucosuria and natriuresis, which complements loop diuretic action at the thick ascending limb of Henle. This synergistic nephron blockade facilitates fluid clearance while avoiding excessive intravascular volume contraction.

However, the progressive increase in diuretic efficiency observed over two months suggests mechanisms extending well beyond simple osmotic diuresis. Specifically, dapagliflozin reduces interstitial fluid overload more selectively than intravascular blood volume, preserving vital organ perfusion. In addition, SGLT2 inhibitors lower central venous pressure, reduce sympathetic overactivity, and improve myocardial energy metabolism. Furthermore, these agents decrease intrarenal interstitial pressure, thereby restoring responsiveness to endogenous natriuretic peptides and exogenous diuretics. As a result, patients maintain clinical stability with lower chronic diuretic requirements.

Clinical Implications for Inpatient Care Pathways

These findings carry substantial implications for modern inpatient heart failure protocols. Clinicians frequently hesitate to initiate novel neurohormonal therapies during acute hospitalization due to concerns regarding transient renal fluctuations or hypotension. However, the DAPA ACT HF-TIMI 68 data indicate that in-hospital initiation accelerates decongestion safely and effectively.

Implementing early in-hospital initiation overcomes outpatient follow-up gaps and establishes optimal foundational therapy before hospital discharge. Moreover, improved diuretic efficiency helps clinicians minimize post-discharge loop diuretic escalation, potentially reducing electrolyte derangements and recurrent hospitalizations. Therefore, acute care protocols should integrate dapagliflozin as early as hemodynamic stability is established. This proactive approach optimizes inpatient decongestion and establishes long-term cardiorenal protection for heart failure patients across the spectrum of left ventricular function.

Safety Considerations and Practice Recommendations

When initiating dapagliflozin in hospitalized patients, clinicians must observe standard monitoring parameters. Initiation is safe once the patient is hemodynamically stable, off intravenous inotropes, and systolic blood pressure remains adequate. Monitoring renal biochemistry and serum potassium within one to two weeks ensures therapeutic safety.

Although transient dips in estimated glomerular filtration rate may occur after SGLT2 inhibitor initiation, these hemodynamic shifts do not reflect true tubular injury. Rather, they signify beneficial reduction in intraglomerular pressure. Clinicians should educate patients on maintaining adequate hydration and recognizing signs of euglycemic ketoacidosis or urinary infections, although these events remain uncommon. Ultimately, incorporating dapagliflozin during the inpatient phase strengthens comprehensive heart failure management and enhances patient recovery.

Frequently Asked Questions

When should clinicians initiate dapagliflozin in patients hospitalized for acute heart failure?

Clinicians should initiate dapagliflozin once the patient achieves clinical and hemodynamic stability. Stabilization criteria include weaning from intravenous inotropic support, stable renal function, and systolic blood pressure of at least 90 to 100 mmHg. Initiating therapy prior to hospital discharge ensures immediate decongestive synergy with loop diuretics and improves long-term medication adherence compared to deferred outpatient prescribing.

How does dapagliflozin improve diuretic efficiency in acute heart failure?

Dapagliflozin enhances diuretic efficiency through complementary proximal tubular natriuresis and selective interstitial fluid clearance. By reducing proximal sodium reabsorption, it increases distal sodium delivery, enhancing loop diuretic efficacy. Over time, dapagliflozin reduces renal congestion and sympathetic tone, allowing patients to achieve greater net fluid removal with lower daily doses of loop diuretics.

Does dapagliflozin cause adverse renal effects when started during hospitalization?

Dapagliflozin demonstrates a favorable renal safety profile in hospitalized heart failure patients. Although a modest, reversible initial dip in estimated glomerular filtration rate often occurs due to tubuloglomerular feedback and reduced intraglomerular hypertension, this hemodynamic adjustment is not indicative of acute kidney injury. In fact, long-term treatment provides robust cardiorenal protection and slows renal function decline.

Disclaimer: This content is for informational and educational purposes only and is not intended to substitute for professional medical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Small AM et al. Effect of In-Hospital Initiation of Dapagliflozin on Decongestion in Patients Hospitalized for Heart Failure: An Analysis of the DAPA ACT HF-TIMI 68 Trial. JACC Heart Fail. 2026 Aug 30. doi: undefined. PMID: 42669075.


2. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574.


3. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117-128.


4. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639.